This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Radius Health Future Growth

Future criteria checks 4/6

Key information

53.5%

Earnings growth rate

50.4%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	10.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	n/a

Recent future growth updates

Recent updates

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Aug 11

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 01

Radius Health on-track for record quarterly revenue for TYMLOS-SC

Dec 15

Earnings and Revenue Growth Forecasts

NasdaqGM:RDUS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	300	36	N/A	N/A	5
12/31/2023	272	12	N/A	N/A	6
12/31/2022	232	-10	N/A	N/A	3
6/30/2022	223	-69	-28	-28	N/A
3/31/2022	217	-73	-44	-44	N/A
12/31/2021	230	-70	-22	-22	N/A
9/30/2021	228	-76	-52	-52	N/A
6/30/2021	249	-60	-62	-62	N/A
3/31/2021	247	-87	-60	-60	N/A
12/31/2020	239	-109	-74	-74	N/A
9/30/2020	232	-113	-54	-54	N/A
6/30/2020	200	-136	-75	-75	N/A
3/31/2020	191	-128	-81	-81	N/A
12/31/2019	173	-133	-82	-82	N/A
9/30/2019	152	-149	-115	-115	N/A
6/30/2019	133	-169	-137	-137	N/A
3/31/2019	115	-203	-169	-169	N/A
12/31/2018	99	-221	-205	-205	N/A
9/30/2018	72	-251	-204	-204	N/A
6/30/2018	58	-259	-217	-215	N/A
3/31/2018	37	-259	-235	-224	N/A
12/31/2017	22	-254	-218	-207	N/A
9/30/2017	14	-236	-216	-204	N/A
6/30/2017	1	-224	-192	-180	N/A
3/31/2017	N/A	-199	-162	-159	N/A
12/31/2016	N/A	-183	-143	-140	N/A
9/30/2016	N/A	-163	-133	-130	N/A
6/30/2016	N/A	-145	-123	-121	N/A
3/31/2016	N/A	-125	N/A	-101	N/A
12/31/2015	N/A	-102	N/A	-87	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDUS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: RDUS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RDUS is expected to become profitable in the next 3 years.

Revenue vs Market: RDUS's revenue (10.1% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: RDUS's revenue (10.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RDUS's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Radius Health Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target increased to US$10.00

Consensus forecasts updated

Radius Health, Inc. Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date moved forward to 2022

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Radius to Be Delisted from the NASDAQ Global Market

Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. (NasdaqGM:RDUS) from Repertoire Partners LP, Velan Capital Investment Management LP and others.

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health

Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome

Price target increased to US$10.00

Patient Square Capital, LP and Gurnet Point Capital Limited entered into a definitive agreement to acquire Radius Health, Inc. (NasdaqGM:RDUS) for approximately $500 million.

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Velan Capital Investment Responds to Radius Health’s Board

Now 24% undervalued after recent price drop

Radius Health, Inc., Annual General Meeting, Jul 08, 2022

Menarini Group and Radius Health, Inc. Present A Subgroup Analysis from the Elacestrant Pivotal Phase 3 EMERALD Clinical Trial At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Radius Health, Inc. Provides Update on Abaloparatide Transdermal System

Velan LP Provides Information to Shareholders of Radius Health Inc

Radius Health, Inc. Appoints Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Consensus forecasts updated

Radius Health, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2022

Consensus forecasts updated

Radius Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Consensus forecasts updated

Consensus forecasts updated

Velan Capital Engages in Discussions with Radius Health

Radius Health Files Supplemental New Drug Application with the Food and Drug Administration for TYMLOS in Men with Osteoporosis

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2022

Reevaluating Radius Health

Forecast breakeven date pushed back to 2023

Radius Announces Update on TYMLOS® (abaloparatide) Label

Radius Health, Inc. Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

Price target decreased to US$20.50

Forecast breakeven date pushed back to 2023

Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)

Price target increased to US$23.86

CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer James Chopas has left the company

Price target decreased to US$22.29

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

Consensus forecasts updated

Consensus forecasts updated

Radius Health, Inc. Reiterates Revenue Guidance for the Full Year of Fiscal 2021

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)

Radius Health EPS misses by $0.02, misses on revenue

Consensus forecasts updated

Analysts update estimates

Full year 2020 earnings released: US$2.35 loss per share (vs US$2.89 loss in FY 2019)

Revenue beats expectations

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Radius Health, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: US$22.94

Revisiting Radius Health

Price target raised to US$22.00

New 90-day high: US$21.60

Radius Health, Inc. Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

Radius Health acquires global rights to RAD011 in Prader-Willi syndrome

Radius Health, Inc. Announces Board Changes

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Radius Health, Inc. Hires Peter Been as Executive Director and Head of Clinical Development for the Abaloparatide Program

New 90-day high: US$18.54

Radius Health on-track for record quarterly revenue for TYMLOS-SC

New 90-day high: US$14.86

Revenue and earnings miss expectations

Third quarter 2020 earnings released: US$0.14 loss per share

New 90-day high: US$13.88

New 90-day low: US$10.80

Radius Health, Inc. Announces Management Changes